Pan-KRAS inhibitor
Pan-KRAS inhibitor for KRAS cancers
estimated prevalence
>500,000
Disease
KRAS+ cancers
Genetic Source
KRAS
Clinical Phase
Pre-clinical
Modality
small molecule
BridgeBio’s pan-KRAS program targets KRASG12D and KRASG12V mutations present in a large percentage of colorectal, pancreatic and non-small cell lung cancer tumors. BridgeBio has achieved in vivo target engagement and has identified leads with promising oral bioavailability. Development candidate selection is planned for 2023.